The Company (Details) numberOfUnits in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2020 USD ($) Segment product	Dec. 31, 2019 USD ($) numberOfUnits	Sep. 30, 2019 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of operating segments | Segment	1
Number of FDA approved products | product	2
Principal amount	$ 316,250,000	$ 316,250,000
Europe
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Total glaucoma market sales		$ 1,000,000,000
Number of units sold | numberOfUnits		105
Estimated market value	4,000,000,000
Revenue from competitive product	300,000,000
United states
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of units sold | numberOfUnits		55
Estimated market value	7,000,000,000
Revenue from competitive product	$ 100,000,000
Convertible notes
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Principal amount			$ 316,250,000
Interest rate			1.50%